共载阿霉素和siRNA的还原敏感型前药纳米粒的制备及体外评价

目的：构建共载阿霉素（DOX）和siRNA的还原敏感型前药纳米粒（PSCSD NPs）,并对其理化性质、细胞摄取和体外细胞毒性进行考察。方法：采用核磁共振氢谱（1H NMR）和傅里叶红外光谱（FT-IR）对羧甲基壳聚糖-二硫键-DOX(CMCSS-DOX)进行结构表征;超声法制备PSCSD NPs,考察其粒径、载药量、包封率、血清稳定性、溶血率和体外释药特性等;采用荧光显微镜和流式细胞术考察4T1细胞对PSCSD NPs的摄取;通过MTT实验测定PSCSD NPs的体外细胞毒性。结果：1H NMR和FT-IR结果表明CMC-SS-DOX成功合成;PSCSD NPs的粒径为（155.1±4.0） nm(PDI=0.144±0.028),Zeta电位为（–29.9±1.0） mV,载药量为（8.25±0.47）%,包封率为（78.41±4.52）%;透射电镜观察PSCSD NPs为球形,且具有良好的血液相容性和血清稳定性。PSCSD NPs具有还原响应释药特性,可在肿瘤部位快速释药。细胞摄取和MTT实验结果表明PSCSD NPs可以有效共载DOX和siRNA进入肿瘤细胞内以发挥抗肿瘤作用。...     

负载替米沙坦PLGA纳米粒的制备与膜渗透性评价

目的 制备和优化替米沙坦聚乳酸-羟基乙酸共聚物(poly lactic-co-glycotic acid, PLGA)纳米粒(TMS-loaded PLGA NPs),并通过Caco-2细胞单层模型评价其体外渗透性。方法 以PLGA作为载体材料,采用溶剂蒸发法制备TMS-loaded PLGA NPs,以替米沙坦质量浓度(x_1)、PLGA质量浓度(x_2)和Poloxamer 188质量浓度(x_3)作为考察因素,以纳米粒的包封率(y_1)和粒径大小(y_2)作为评价指标,通过3因素3水平析因设计优化TMS-loaded PLGA NPs处方;通过透射电镜观察TMS-loaded PLGA NPs的微观形态,比较TMS乙醇溶液和TMS-loaded PLGA NPs的体外药物释放特性;采用Caco-2细胞单层模型评价TMS原料药与TMS-loaded PLGA NPs的跨膜转运情况。结果 TMS-loaded PLGA NPs的最优处方组成：替米沙坦的质量浓度为14.0 mg·mL^(-1),PLGA的质量浓度为35.0 mg·mL(-1),PLGA的质量浓度为35.0 mg·mL^(-1),Poloxamer 188的质量浓度为5.0 mg·mL(-1),Poloxamer 188的质量浓度为5.0 mg·mL^(-1)。制备的纳米粒粒径为(159.6±18.3) nm,包封率为92.1%±1.6%;透射电镜下可观察到TMS-loaded PLGA NPs呈圆整球状,分散性良好;TMS-loaded PLGA NPs释药较为平缓,24 h药物释放量达到87%;TMS-loaded PLGA NPs能够有效增加药物的渗透性。结论 以PLGA作为载体,将替米沙坦制备成PLGA NPs,有望提高药物的口服生物利用度。     

载姜黄素的壳寡糖接枝布洛芬纳米粒的研制

以1-(3-二甲基氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC·HCl)为偶联剂,将布洛芬(IBU)接枝于壳寡糖(COS)上,并采用自组装法制备壳寡糖接枝布洛芬纳米粒(COS-g-IBU NPs)。以COS-g-IBU NPs为载体,使用超声振荡技术制备负载姜黄素纳米粒(1-COS-g-IBU NPs)。结果表明,COS-g-IBU NPs的临界胶束浓度为(24.6±0.2)μg/ml,COS-g-IBU NPs和1-COS-g-IBU NPs的形态为类球形,平均粒径分别为80和132 nm。所得纳米粒的包封率为(96.35±0.32)%,载药量为(8.79±0.03)%,体外释放试验表明1-COS-g-IBU NPs具有明显的缓释作用。     

无稳定剂修饰的汉防己甲素PLGA纳米粒制备及体外评价

目的:制备无稳定剂修饰的汉防己甲素PLGA纳米粒,研究其理化性质及细胞毒和细胞摄取特性。方法:以聚乳酸-羟基醋酸共聚物(PLGA)为载体材料,采用无稳定剂修饰的纳米沉淀法制备汉防己甲素纳米粒;通过单因素试验考察不同制备工艺对纳米粒理化性质的影响;通过载药量、包封率、累积释药量等指标考察其载药特性;采用MTT比色法检测其对人肺腺癌细胞株A549的细胞毒性;采用共聚焦显微镜技术考察其细胞摄取特性。结果:无稳定剂修饰的汉防己甲素PLGA纳米粒平均粒径169.3 nm,与有稳定剂的汉防己甲素PLGA纳米粒相比外观无明显改变。在一定范围内,随着PLGA用量的增加,纳米粒的粒径呈上升趋势;随着投药量的增加,纳米粒的载药量显著增加,包封率下降。在pH7.4的释放介质中,纳米粒释慢释药,96 h累积释药率60.44%。细胞毒试验显示,当培养时间为8 h时,汉防己甲素组的细胞毒性大于汉防己甲素纳米粒组;当培养时间延长至24 h时,汉防己甲素纳米粒组的细胞活性明显低于纯药物组;高剂量的空白纳米粒组始终表现较低的细胞毒性。激光共聚焦电镜断层扫描显示汉防己甲素纳米粒能够较好的被细胞摄取。结论:制备的无稳定剂修饰的汉防己甲素PLGA纳米粒大小均一,包封率高,体外释药表现出较好的缓释效果,易被细胞摄取,对A549细胞的增殖有明显的抑制作用。     

芍药苷聚乳酸-羟基乙酸共聚物纳米粒制备工艺的优化及对心肌细胞的保护作用

目的:优化芍药苷聚乳酸-羟基乙酸共聚物(PLGA)纳米粒制备工艺,并探讨芍药苷PLGA纳米粒对H₂O₂诱导损伤的H9c2心肌细胞的保护作用。方法:首先使用复乳-溶剂挥发法制备芍药苷PLGA纳米粒,采用Plackett-Burman设计实验以及Box-Behnken响应面设计实验对其制备工艺进行优选,得出最佳处方,并对按最佳处方制备的芍药苷PLGA纳米粒进行表征分析、4℃储藏稳定性考察以及体外释放考察;最后通过H₂O₂诱导建立大鼠H9c2心肌细胞氧化损伤模型,考察芍药苷PLGA纳米粒对心肌细胞的保护作用,CCK-8法检测细胞存活率,试剂盒检测心肌细胞乳酸脱氢酶(LDH)漏出量、丙二醛(MDA)、超氧化物歧化酶(SOD)的含量。结果:最佳处方：泊洛沙姆浓度为0.4%,给药量为3.1 mg, PLGA为21.4 mg;所得芍药苷PLGA纳米粒包封率为(45.49±0.29)%,载药量为(4.52±0.05)%,粒径为(115.1±3.61) nm,多分散系数(polydiseperse index, PD...     

壳聚糖与细胞穿透肽共修饰的纳米粒制备及抗结肠癌的体外细胞学评价

目的:为了提高5-氟尿嘧啶(5-FU)抗结肠癌的口服疗效,构建了一种由N,N,N-三甲基-N-硬脂酰壳聚糖(TSCS)、腺苷和细胞穿透肽(TAT)共修饰的聚乳酸-羟基乙酸共聚物(PLGA)纳米粒,并对其进行相关评价。方法:合成TSCS、硬脂酰腺苷与5-FU磷脂复合物,制备了腺苷穿透肽共修饰纳米粒(AD-CPP-NPs),并对其进行粒径、包封率、体外释放等药剂学和细胞学评价。结果:纳米粒外观为类球形,分布均一。测得纳米粒粒径约为177 nm, Zeta电位为38.2 mV,包封率为56.6%。细胞实验表明,与HT-29细胞共孵育4 h后,与表面未修饰的PLGA纳米粒相比,共修饰纳米粒摄取能力相对聚乙烯醇纳米粒提高16.42倍。结论:共修饰纳米粒能主动靶向结肠癌细胞、增强细胞摄取效率、增加5-FU在癌细胞内的蓄积。     

紫杉醇PLGA纳米粒的处方优化与评价

目的 采用生物可降解材料乳酸-羟基乙酸共聚物(PLGA)为载体,比较不同的制备方法和工艺对紫杉醇(PTX)PLGA纳米粒(PTX-PLGA NPs)粒径的影响,筛选出最优制备工艺,并考察所制备纳米粒的体外表征以及对人源胃癌细胞SGC-7901的抗肿瘤效果,为紫杉醇缓释制剂在胃癌中的开发提供一定的实验基础.方法 采用单因...     

共载阿霉素-碳点@磷酸钙脂质纳米粒的制备与评价

目的制备共载阿霉素-碳点@磷酸钙脂质纳米粒(Doxorubicin-carbon dots@lipid coated calcium,DOX-CDs@LCP NPs),并对其载药性能及体外释药行为进行评价。方法采用反相微乳法制备DOX-CDs@LCP NPs,考察钙/磷比值,内水相pH值及搅拌速度对纳米粒外观的影响;并对阿霉素和碳点浓度对制剂载药量的影响进行考察。通过激光散射粒径测定仪测定粒径和电位,采用透射电镜表征纳米粒形态。同时以不含碳点的纳米粒(DOX@LCP NPs)作为对照。比较两种制剂在体外释药行为上的差异。结果 DOX-CDs@LCP NPs带有磷酸钙内核,外层有磷脂包裹,平均粒径为133.9 nm,zeta电位为-20 mV,包封率和载药量质量分数分别为(64.38±2.4)%、(12.22±0.53)%;在生理条件下,DOX-CDs@LCP能够延缓药物释放达29.9%;在酸性环境下,药物释放加速,累积释放量可达78%。结论 DOX-CDs@LCP NPs具有较高的载药量和体外释药性能。     

N-琥珀酰壳聚糖纳米粒肿瘤靶向性及抗肿瘤活性评价

目的 评价N-琥珀酰壳聚糖纳米粒(Suc-Chi/NPs)肿瘤靶向性,考察5-氟尿嘧啶-N-琥珀酰壳聚糖纳米粒(5-FU-Suc-Chi/NPs)抗肿瘤活性。方法 建立异硫氰基荧光素(FITC)-Suc-Chi/NPs的体内荧光分析方法,检测Suc-Chi/NPs在Sarcoma 180-荷瘤小鼠体内组织分布数量。采用荧光显微镜观察FICT-Suc-Chi/NPs在组织切片中蓄积量,评价FICT-Suc-Chi/NPs肿瘤靶向性;以Suc-Chi/NPs、5-FU注射液为对照,考察5-FU-Suc-Chi/NPs在Sarcoma 180-荷瘤小鼠体内的瘤体积抑制率及对荷瘤小鼠体重的影响,评价制剂的疗效及不良反应。结果 FICT-Suc-Chi/NPs能够长时间的滞留在血液中,在各组织及血浆中分布的数量次序依次为肾>肿瘤>血液>肝>脾>肺。5-FU-Suc-Chi/NPs与5-FU注射液相比较,能够更有效地抑制Sarcoma 180肿瘤的生长,而且组织毒性较温和。结论 研究表明N-琥珀酰壳聚糖纳米粒具有长循环特性,能够实现实体肿瘤靶向传递;以N-琥珀酰壳聚糖为载体包载抗肿瘤模型药纳米粒具有较高抗肿瘤活性及较低的毒性。     

载羟基喜树碱纳米粒的制备和体外评价

目的:制备壳寡糖接枝布洛芬(COS-g-IBU)纳米粒负载羟基喜树碱(HCPT)纳米粒,并考察其体外释药性能。方法:以1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)为偶联剂,制备壳寡糖接枝布洛芬纳米粒(COS-g-IBU NPs)。以COS-g-IBU NPs为载体,使用超声振荡技术制备负载HCPT的壳寡糖接枝布洛芬纳米粒(HCPT-COS-g-IBU NPs)。结果:透射电镜照片显示COS-g-IBU NPs和HCPT-COS-g-IBU NPs为球形,平均粒径分别为(116±2)nm和(146±5)nm,测得药物包封率为(79.24±1.18)%,载药量为(3.62±0.05)%,体外药物释放试验表明HCPT-COS-g-IBU NPs具有明显的缓释作用。结论:COS-g-IBU可作为HCPT缓释载体材料。     

Polyketal Nanoparticles Co-Loaded With miR-124 and Ketoprofen for Treatment of Rheumatoid Arthritis

Ketoprofen, a non-steroidal anti-inflammatory drug, can effectively relieve pain associated with arthritis, and microRNA-124 (miR-124) can inhibit the progression of the disease. In this study, poly (cyclohexane-1,4-diylacetone dimethylene ketal) (PCADK) nanoparticles (NPs) co-loaded with ketoprofen and miR-124 were successfully prepared using an emulsified solvent evaporation method. The co-loaded NPs exhibited a mean particle diameter of 160 nm. The acid sensitivity of the NPs was determined through in vitro release experiments. An adjuvant-induced arthritis rat model of arthritis was established for evaluating the pharmacodynamics of the NPs through clinical scoring and degree of swelling. The PCADK NPs exhibited more potent pharmacodynamic effects owing to the acid-sensitive properties of the carrier materials, compared with Poly (lactic-co-glycolic acid) (PLGA) NPs. Furthermore, PCADK co-loaded NPs exhibited superior anti-inflammatory effects compared to NPs loaded with either miR-124 or ketoprofen alone. In conclusion, co-delivery of ketoprofen and miR-124 through NPs is a promising strategy for the treatment of arthritis.     

A one-step process in preparation of cationic nanoparticles with poly(lactide-co-glycolide)-containing polyethylenimine gives efficient gene delivery

A one-step preparation of nanoparticles with poly(lactide-co-glycolide) (PLGA) pre-modified with polyethylenimine (PEI) is better in requirements for DNA delivery compared to those prepared in a two-step process (preformed PLGA nanoparticles and subsequently coated with PEI). The particles were prepared by emulsification of PLGA/ethyl acetate in an aqueous solution of PVA and PEI. DLS, AFM and SEM were used for the size characteristics. The cytotoxicity of PLGA/PEI nanoparticles was detected by MTT assay. The transfection activity of the particles was measured using pEGFP and pβ-gal plasmid DNA. Results showed that the PLGA/PEI nanoparticles were spherical and non-porous with a size of about 0.2 μm and a small size distribution. These particles had a positive zeta potential demonstrating that PEI was attached. Interestingly, the zeta potential of the particles (from one-step procedure) was substantially higher than that of two-step process and is ascribed to the conjugation of PEI to PLGA via aminolysis. The PLGA/PEI nanoparticles were able to bind DNA and the formed complexes had a substantially lower cytotoxicity and a higher transfection activity than PEI polyplexes. In conclusion, given their small size, stability, low cytotoxicity and good transfection activity, PLGA/PEI-DNA complexes are attractive gene delivery systems.     

Skin photoprotection improvement: synergistic interaction between lipid nanoparticles and organic UV filters

The main objective of this study was to prepare two types of nanoparticles with poly(d,l-lactide-co-glycolide) (PLGA) and polyethylenimine (PEI) polymers. Plasmid DNA (pDNA) was adsorbed either on PLGA/PEI nanoparticles, or as PEI/DNA complex onto the surface of PLGA nanoparticles. Both types of nanoparticles were prepared by the double emulsion method. The nanoparticles were characterized by their size, zeta potential and pDNA or PEI/DNA complex adsorption. The PEI/DNA complex adsorption was confirmed with ethidium bromide assay. pDNA adsorption onto PLGA/PEI nanoparticles (PLGA/PEI-DNA) was studied by electrophoresis on agarose gel. Cytotoxicity and transfection efficiency of both types of nanoparticle and PEI/DNA complexes formulations were studied in head and neck squamous carcinoma cell line (FaDu). To improve endosomal release, photochemical internalization (PCI) was used. The zeta potential increased when the PEI/DNA complex adsorbed onto PLGA nanoparticles (PLGA-PEI/DNA). Optimal pDNA adsorption efficiency was achieved for nitrogen/phosphorous ratio≥20/1. In vitro transfection and cells viability on FaDu cells with or without PCI were found to be variable depending on the type and concentration of nanoparticles. The results showed that transfection efficiency for PLGA/PEI-DNA or PLGA-PEI/DNA nanoparticles ranged between 2 and 80%, respectively. PCI was found to slightly improve the transfection efficiency for all formulations.     

A computer-aided chem-photodynamic drugs self-delivery system for synergistically enhanced cancer therapy

The therapeutic strategy that gives consideration to the combination of photodynamic therapy and chemotherapy, has emerged as a potential development of effective anti-cancer medicine. Nevertheless, co-delivery of photosensitizers (PSs) and chemotherapeutic drugs in traditional carriers still remains great limitations due to low drug loadings and poor biocompatibility. Herein, we have utilized a computer-aided strategy to achieve a desired carrier-free self-delivery of pyropheophorbide a (PPa, a common PS) and podophyllotoxin (PPT, a classical chemotherapeutic drug) for synergistic cancer therapy. First, the computational simulation method identified the similar molecular sizes and rigid molecular structures between two drugs molecules. Based on the molecular docking, the intermolecular interactions were found to include π-π stackings, hydrophobic interactions and hydrogen bonds. Next, both drugs could co-assemble into nanoparticles (NPs) via one-step nanoprecipitation method. The various spectral experiments (UV, IR and FL) were conducted to evaluate the formation mechanism of spherical NPs. Moreover, in vitro and in vivo experiments systematically demonstrated that PPT/PPa NPs not only showed better cellular uptake efficiency, stronger cytotoxicity and higher accumulation in tumor sites, but also exhibited synergistic antitumor effect in female BALB/C bearing-4T1 tumor mice. Such a computer-aided design strategy of chem-photodynamic drugs self-delivery systems pave the way for efficient synergistic cancer therapy.     

阿霉素修饰纳米银的制备及其体外抗肿瘤活性研究

摘要： 目的 设计合成一类新型的具有pH响应性的阿霉素-纳米银 （DOX-Ag NPs） 联合抗肿瘤药物, 对其理化性质进行表征, 并研究其体外响应性释药行为和抗肿瘤活性。方法 通过硫辛酰肼 （LA-NHNH2 ） 连接纳米银 （Ag NPs） 和阿霉素 （DOX）, 得到DOX-Ag NPs。利用核磁氢谱 （1 H NMR） 和高分辨质谱 （HRMS） 对硫辛酰肼-阿霉素 （LA- NHN=DOX） 进行结构确证; 通过动态光散射 （DLS） 和透射电镜 （TEM） 分析纳米粒的粒径和形貌; 通过紫外-可见吸收光谱和荧光光谱表征纳米粒的光学性质; 通过透析法结合荧光光谱检测DOX-Ag NPs在不同pH下的DOX释放行为; 采用噻唑蓝比色法研究DOX-Ag NPs对HepG2肿瘤细胞的增殖抑制效果。结果 LA-NHN=DOX的1 H NMR数据及HRMS检测到746.275 6处的分子离子峰均证明LA-NHN=DOX成功合成。DOX-Ag NPs为粒径 （40.4±3.8） nm的球形纳米粒; 在弱酸性条件下DOX-Ag NPs能够快速响应性释放DOX; DOX-Ag NPs对HepG2肿瘤细胞增殖抑制呈现浓度依赖性, 当DOX浓度为0.5~20 mg/L （Ag浓度为0.45~18 mg/L） 时, DOX-Ag NPs组细胞生存率均明显低于DOX 组和Ag NPs组 （均P＜0.05）。结论 DOX-Ag NPs是一种具有pH响应性的联合抗肿瘤纳米制剂, 能在肿瘤组织快速释放DOX, 并通过与Ag NPs的协同治疗, 发挥良好的体外抗肿瘤作用。     

Preparation and improvement of release behavior of chitosan microspheres containing insulin

Sophisticated delivery systems, such as nanoparticles, represent a growing area in biomedical research. Nanoparticles (Np) were prepared using a solvent emulsion evaporation method (SEEM) to load zinc(II) phthalocyanine (ZnPc). Np were obtained using poly (d,l latic-co-glycolic acid) (PLGA). ZnPc is a second generation of photoactive agents used in photodynamic therapy.

ZnPc loaded PLGA nanoparticles were prepared by SEEM, characterized and available in cellular culture. The process yield and encapsulation efficiency were 80 and 70%, respectively. The nanoparticles have a mean diameter of 285 nm, a narrow size distribution with polydispersive index of 0.12, smooth surface and spherical shape. ZnPc loaded nanoparticles maintains its photophysical behavior after encapsulation. Photosensitizer release from nanoparticles was sustained with a moderate and burst effect of 15% for 3 days. The photocytotoxicity of ZnPc loaded PLGA Np was evaluated on P388-D1 cells what were incubated with ZnPc loaded Np (5 μM) by 6 h and exposed to red light (675 nm) for 120 s, and light dose of 30 J/cm². After 24 h of incubation, the cellular viability was determined, obtaining 61% of cellular death. All the physical–chemical, photophysical and photobiological measurements performed allow us conclude that ZnPc loaded PLGA nanoparticles is a promising drug delivery system for photodynamic therapy.     

Development of Nanoparticles for Drug Delivery to Brain Tumor: The Effect of Surface Materials on Penetration Into Brain Tissue

Surface-modified poly(d,l-lactic-co-glycolic acid) PLGA nanoparticles (NPs) were fabricated via nanoprecipitation for obtaining therapeutic concentration of paclitaxel (PTX) in brain tumor. The cellular uptake and cytotoxicity of NPs were evaluated on C6 glioma cells in vitro, and BALB/c mice were used to study the brain penetration and biodistribution upon intravenous administration. Results showed that by finely tuning nanoprecipitation parameters, PLGA NPs coated with surfactants with a size around 150 nm could provide a sustained release of PTX for >2 weeks. Surface coatings could increase cellular uptake efficiency when compared with noncoated NPs, and d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) showed the most significant enhancement. The in vivo evaluation of TPGS-PLGA NPs showed amplified accumulation (>800% after 96 h) of PTX in the brain tissue when compared with bare NPs and Taxol^®. Therefore, PLGA-NPs with PLGA-TPGS coating demonstrate a promising approach to efficiently transport PTX across blood-brain barrier in a safer manner, with the advantages of easy formulation, lower production cost, and higher encapsulation efficiency.     

Multifunctional poly (lactide-co-glycolide) nanoparticles for luminescence/magnetic resonance imaging and photodynamic therapy

Poly (lactide-co-glycolide) (PLGA) coupled with methoxy poly (ethylene glycol) (mPEG) or chlorin e6 (Ce6) was synthesized using the Steglich esterification method. PLGA-linked mPEG (PLGA-mPEG), PLGA-linked Ce6 (PLGA-Ce6), and Fe(3)O(4) were utilized to constitute multifunctional PLGA nanoparticles (～160 nm) via the multi-emulsion W(1)/O/W(2) (water-in-oil-in-water) method. The photo-sensitizing properties of Ce6 molecules anchored to PLGA nanoparticles enabled in vivo luminescence imaging and photodynamic therapy for the tumor site. The encapsulation of Fe(3)O(4) allowed high contrast magnetic resonance (MR) imaging of the tumor in vivo. Overall, PLGA nanoparticles resulted in a significant tumor volume regression for the light-illuminated KB tumor in vivo and enhanced the contrast at the tumor region, compared to that of Feridex(?) (commercial contrast agent).     

PLGA-TPGS 负载α-TIF-siRNA 纳米粒对疱疹病毒1的抑制作用

目的：研究以 PLGA-TPGS 生物可降解材料为载体包载α-TIF-siRNA 的纳米粒对 HSV1的抑制作用。方法以 PLGA-TPGS 为载体,采用双乳蒸发法制备包载α-TIF-siRNA 的 PLGA-TPGS 纳米粒（命名为 PLGA-TPGS/α-TIF-siRNA NPs）,并对其进行表征,包括粒径大小、zeta 电位、包封率和释放率,用 MTT 法检测纳米粒对上皮细胞和HeLa 细胞的细胞毒作用,免疫荧光观察纳米粒在细胞内的释放,用空斑实验研究体外研究纳米粒对 HSV1病毒的抑制作用。结果 PLGA-TPGS/α-TIF-siRNA NPs 的粒径大小为（257±2.94）nm,zeta 电位为（-31.25±1.70）mV,siRNA的包封率为（56.23±3.68）％,纳米释放 siRNA 呈双相,即在96 h 释放达到50％,之后呈缓慢释放,用 MTT 法分析 PL-GA-TPGS/α-TIF-siRNA NPs 对原代角质形成细胞和 HeLa 细胞几乎无细胞毒性。荧光显微镜能观察纳米粒 siRNA 细胞内释放。PLGA-TPGS/α-TIF-siRNA NPs 能明显延长抑制感染 HeLa 细胞的 HSV1。结论 PLGA-TPGS 纳米粒可以作 siRNA 的载体。PLGA-TPGS/α-TIF-siRNA NPs 在体外对 HSV1病毒具有明显的抑制作用,可以成为治疗 HSV1-诱导的角膜炎在内的相关疾病的候选药物。